Sofía Pérez, Agustín Rey, Pedro Lara, José Marín, Elena Redondo, Rosa Apolinario.
Baak JPA, Van DH, Kurver PHJ et al. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374- 382.
Cheville JC, Terrell RB, Cohen MB. Use of proliferative markers Ki67(MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis. Mod Pathol 1994; 7:794-800.
Chiang PH, Huang MS, Tsai CJ, Tsai EM, Huang CH, Chiang CP.Transitional cell carcinoma of the renal pelvis and ureter in Taiwan. Cancer 1993; 71:3988-92.
Chyle V, Pollack A, Czerniak B, Stephens LC, Zagars GK, Terry NH et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 1996; 35 (2): 281-287.
Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, et al. The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol 1992; 21:48-50.
Cox DR. Regression models and life-tables. J.R. Stat Soc (B) 1972; 34:187-220.
Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Reymond R. Adjuvant radiotherapy in high stage transitional cell carcinoma of the renal pelvis and ureter. Int J Radiat Oncol Biol Phys 1992; 24:743-5.
Cummings KB. Nephroureterectomy: Rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1991; 23:569-578.
El-Abadi H, Nagel R. Transitional cell carcinoma of the renal pelvis and ureter:prognostic relevance of nuclear deoxyribonucleic acid ploidy studied by slide cytometry: an 8-year study. J Urol 1992; 148:31-7.
Flemming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy, BJ, editors. American Joint Committee on Cancer staging manual. 5th ed. Philadelphia: JB Lippincott, 1997.
Gerber GS, Lyon ES. Endopyelotomy: patient selection, results, and complications. Urology 1994; 43:2-10.
Kaplan EI & Meier P. Non parametric estimation from incomplete observations. J Am Stat Ass, 1958;53:457-81.Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implicatrions in tissue kinetics. Br J Cancer 1972; 26: 239-257.
King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996; 155: 316-320.
Kobayasi H, Obata K. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph node metastasis. Cancer Chemother Pharmacol 1994; 35 Suppl: S14-7.
Lane DP. P53: the guardian of the genome. Nature 1992;358:15-16.
Lipponen P. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer 1993; 53:365-370.
Lipponen P.K., Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis J Pathol 1994; 173: 333-339.
Masuda M, Takano Y, Iki M, Tomoyuki A, Hashiba T, Noguchi S, Hosaka M. Apoptosis in transitional cell carcinoma of the renal pelvis and ureter: association with proliferation, bcl-2 and prognosis. J Urol 1997; 118: 750-753.
Melamed MR, Reuter VE. Pathology and staging of urothelial tumors of the kidney and the ureter. Urol Clin North Am 1993; 20: 333-47.
Mellemgaard A, Carstensen B, Norgaard N, Knudsen JB, Olsen JH.Trends in the incidece of cancer of the kidney, pelvis, ureter and bladder in Denmark. 1943-1988. Scand J Urol Nephrol 1993; 27:327-32.
Meyn RE, Stephens LC, Ang KK, Hunter NR, Brock WA, Milas L , et al. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol. 1993; 64: 583-591 (a).
Meyn RE, Stephens LC, Hunter NR, Milas L . Apoptosis inmurine tumors treated with chemotherapy agents. Anticancer Drugs 1995; 6:443-450.
Nylander K, Nilsson P, Mehle C, Ross G. P53 mutation, protein expression and cell proliferation in squamous cell carcinomas of the head and neck.Br J Cancer 1995;71:825-830.
Peto R, Pike MC, Armitage P, Breslow NE,Cox DR,Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35:1-39.
Rey, A, Lara P, Redondo E, Valdés E, Apolinario R. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer 1997;79:2178-2185.
Tasca A, Zattoni F. The case for percutaneous approach to transitional cell carcinoma of the renal pelvis. J Urol 1990; 143: 901-4.
Walker NI. Harmon BV, Gobe GC, Kerr JFR. Patterns of cell death. Methods Achiev Exp Pathol 1988; 13: 18 54.